Grant Performance Report Ghana External Print Version GHA-M-MOH Last Updated on: 02 July 2015 General SSF Information Country Ghana SSF Agreement Number GHA-M-MOH SSF Title Accelerating Access to Prevention, Treatment, and Home Based Care for Malaria and Increasing the Access to Affordable ACTs in the Private Sector Principal Recipient The Ministry of Health of the Republic of Ghana SSF Status Financial Closure - End date SSF Start Date Current* Implementation Period Start Date Component 01 Jul 2011 SSF End Date Current* 01 Mar 2015 Implementation Period End Date Malaria Last Round 09 31 Dec 2017 31 Dec 2017 Latest Rating Current* Implementation Period Signed Amount $ 118,095,102 Current* Implementation Period Committed Amount $ 44,076,337 Current* Implementation Period Disbursed Amount $ 16,279,018 Cumulative Signed Amount $ 180,817,857 Cumulative Committed Amount $ 106,799,092 Cumulative Disbursed Amount $ 79,001,773 % Disbursed Time Elapsed (at the end of the latest reporting period) 74% 36 months * Latest Implementation Period if SSF is closed page 1 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 New GPR Report - Table of Contents (For ExternalVersion) 1. Program Description and Contextual Information 1.1. Grant Summary - Web 1.2. Country Latest Statistics 1.3. Comments on Key Discrepancies between Approved Proposal and Grant Agreement 1.4. Conditions Precedent 2. Key Grant Performance Information 2.1. Program Impact and Outcome Indicators 2.2. Programmatic Performance 2.2.1. Reporting Periods 2.2.2. Program Objectives, Service Delivery Areas and Indicators 2.2.3. Cumulative Progress To Date 2.3. Financial Performance 2.3.1. Grant Financial Key Performance Indicators (KPIs) 2.3.2. Program Budget 2.3.3. Program Expenditures 2.3.4. Graph - Cumulative Program Budget, Expenditures and Disbursement to Date 2.4. Progress Update and Disbursement Information 2.5. Contextual Information 2.6. Phase 2 Grant Renewal page 2 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 1. Program Description and Contextual Information 1.1. Grant Summary - Web 1.2. Country Latest Statistics Malaria Estimate Year Source Estimated malaria cases, 2010 6,527,901 2012 World Malaria Report 2012 Estimated malaria deaths, 2010 12,575 2012 World Malaria Report 2012 Malaria: probable and Confirmed (total), 2011 3,240,791 2012 World Malaria Report 2012 Malaria: suspected (total), 2011 4,154,261 2012 World Malaria Report 2012 Nets distributed (ITNs & LLINs) 13,548,816 2014 Mid-2014 Global Fund Results Background and Health Spending Estimate Year Source Population, total 25,366,462 2012 The World Bank Group (Data latest 2013 update: 2012 Birth rate, crude (per 1,000 people) 31 2011 The World Bank Group (Data latest 2013 update: 2011 Death rate, crude (per 1,000 people) 8 2011 The World Bank Group (Data latest 2013 update: 2011 External resources for health (% of total expenditure on health) 14 2011 The World Bank Group (Data latest 2013 update: 2011 Health expenditure per capita (current US$) 75 2011 The World Bank Group (Data latest 2013 update: 2011 Health expenditure, private (% of GDP) 2 2011 The World Bank Group (Data latest 2013 update: 2011 Health expenditure, public (% of GDP) 3 2011 The World Bank Group (Data latest 2013 update: 2011 Health expenditure, public (% of government expenditure) 12 2011 The World Bank Group (Data latest 2013 update: 2011 Health expenditure, public (% of total health expenditure) 56 2011 The World Bank Group (Data latest 2013 update: 2011 Health expenditure, total (% of GDP) 5 2011 The World Bank Group (Data latest 2013 update: 2011 Hospital beds (per 1,000 people) 1 2011 The World Bank Group (Data latest 2013 update: 2011 Life expectancy at birth, total (years) 64 2011 The World Bank Group (Data latest 2013 update: 2011 Nurses and midwives (per 1,000 people) 1 2010 The World Bank Group (Data latest 2013 update: 2010 Physicians (per 1,000 people) 2010 The World Bank Group (Data latest 2013 update: 2010 Community health workers (per 1,000 people) 2008 The World Bank Group (Data latest 2013 update: 2008 page 3 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 1.3. Comments on Key Discrepancies between Approved Proposal and Grant 1.5. Conditions Precedent CP CP Type # Condition Precedent Functional Tied To Area Terminal Date Is curr Comments ently met? Condition Precedent Conditions applicable as of Implementation Period 2 (signed July 2013) Met Condition Precedent 1. Condition(s) Precedent to the Use of Grant Funds for strengthening of Supply Chain Management Systems The use of Grant funds by the Principal Recipient for the activities to strengthen the supply chain management systems is subject to satisfaction of each of the following conditions: a. the delivery by the Principal Recipient to the Global Fund of a Supply Chain Improvement Master plan (the “Master Plan”), in form and substance satisfactory to the Global Fund, prepared by the Procurement and Supply Management Thematic Working Group in collaboration with technical partners and the principal recipients of Global Fund grants in Ghana; b. the delivery by the Principal Recipient to the Global Fund of a work plan and budget defining the activities financed through the Master Plan and identifying a suitable entity to implement the Master Plan, (“the Implementing Entity”) selected by key technical partners; and c. the written approval of the Global Fund of the Master Plan, work plan and budget, and the Implementing Entity. Met The PR together with partners participated in development of the Supply Chain Master Plan which was completed in January 2013. However, the plan is yet to be approved by the new Minister of Health (started February 2013) and the scope and areas of interventions to be funded by the US$2 million is yet to be agreed upon. The fulfilment of this condition is delayed for the abovementioned reasons; however it is outside of the PR control to influence its completion. NMCP grant was used as a mean to channel funds for supply chain improvement. The agreement on areas to finance by the US$2 million is to be agreed upon by GF and Partners with the involvement of PR. Condition Precedent 2. Condition(s) Precedent to the Use of Grant Funds for Malaria Indicator Survey The use of Grant funds by the Principal Recipient for Malaria Indicator Survey (the “MIS”) is subject to the satisfaction of each of the following conditions: a. the delivery by the Principal Recipient to the Global Fund of a plan for the implementation of the MIS, in form and substance satisfactory to the Global Fund, including the scope of work and detailed budget for the survey developed in collaboration with technical partners in Ghana; and b. the written approval of the Global Fund of the work plan and budget. Met The PR submitted the budget for the Ghana Demographic and Health Survey which includes all the key malaria indicators to the Global Fund. The Global Fund approved the plan and budget for the implementation of the MIS on 8 July 2014. 30.Apr.14 page 4 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 CP CP Type # Condition Precedent Condition Precedent 3. Condition(s) Precedent to the Use of Grant Funds for Health System Strengthening (HSS) and District Health Information Management System (DHIMS) Strengthening Activities Functional Tied To Area Terminal Date Is curr Comments ently met? 30.Apr.14 Met The use of Grant funds by the Principal Recipient for HSS and DHIMS Strengthening activities is subject to satisfaction of each of the following conditions: a. the delivery by the Principal Recipient to the Global Fund of a plan for the implementation HSS and DHIMS strengthening activities, in form and substance satisfactory to the Global Fund, including the scope of work and detailed budget for the activities developed in collaboration with technical partners in Ghana; and b. the written approval of the Global Fund of the work plan and budget. The Principal Recipient acknowledges and agrees that the Grant funds allocated for HSS and DHIMS Strengthening Activities may be re-allocated for other purposes as determined by the Global Fund. Condition Precedent Special condition 1: For the avoidance of doubt, the Principal Recipient acknowledges that the amount set forth in block 8 of the face sheet of this Agreement represents the total funding for this Grant from the start of the first Implementation Period to the end of the current Implementation Period, and, therefore, nothing in this Agreement shall be interpreted to mean that the entire amount in block 8 of the face sheet of this Agreement is available during the current Implementation Period. 28.Feb.15 Met Condition Precedent Special condition 2: Throughout the Term of this Agreement, unless otherwise determined by the Global Fund, the procurement of the following health products shall be conducted by VPP: ACTs, Artesunate injections, Quinine tablets and injections, Amodiaquine tablets, S/P tablets, RDTs and LLINs. All other health products procurement shall be conducted by the MoH Procurement and Supply Division. Procurement of nonHealth Products shall be done by the competent entity under the Ghana Health Services or the Ministry of Health, as approved by the Global Fund. The Principal Recipient shall ensure full compliance with applicable policies on Procurement and Supply Management of the Global Fund. The Principal recipient shall submit to the Global Fund (or its designated agent) all specifications and tender documents, before the advertising and awarding of tenders. Met PR submitted the plan and budget for DHIMS strengthening on 20 August 2013 (total budget for US$2.5mln). The plan and budget were reviewed by the Global Fund and approved by the FPM on 20 November 2013. Total final budget approved is $1,571,780. valid throughout the grant The procurement of ACTs, Artesunate injections, Quinine tablets and injections, Amodiaquine tablets, S/P tablets, RDTs and LLINs is done through VPP. According to the CP, all other health products procurement shall be conducted by the MoH Procurement and Supply Division. Also, procurement of non-Health Products shall be done by the competent entity under the Ghana Health Services or the Ministry of Health, as approved by the Global Fund. In view of this, the existing arrangement arising from a meeting held on 21st December 2010 where health equipment, reagents and consumables are procured by Supplies, Stores and Drug Management Directorate (SSDM) of the Ghana Health Service should be revised to reflect the new requirement. The existing arrangement requires all tender and evaluation documents to be submitted to GF/LFA for review prior to award of contract. This is expected to ensure compliance with applicable policies on Procurement and Supply Management of the Global Fund. page 5 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 CP CP Type # Condition Precedent Functional Tied To Area Terminal Date Is curr Comments ently met? Condition Precedent Special condition 3: By no later than 30 September 2013, the Principal Recipient shall deliver to the Global Fund a plan, in form and substance satisfactory to the Global Fund, to strengthen its financial controls and monitoring at the Regional and District level, including mechanisms of capturing and accounting for the revenues from income generating activities under the Program, namely sales of commodities, including but not limited to ACT and RDT. 30.Sep.13 Met This condition is overdue, The Ministry of Health and the Ghana Health Service quantified the potential revenue generated from the sale of ACTs procured with Global Fund resources. The PR indicated that the report has been presented to the Minister of Health who instituted a verification of the conclusions by the Internal Audit of the Ministry of Health. However, the Minister is yet to grant approval for the submission of the report to the Global Fund. Condition Precedent Special condition 4: By no later than 30 September 2013, the Principal Recipient shall submit to the Global Fund a revised Internal Audit Plan (IAP), in form and substance satisfactory to the Global Fund, which shall include a detailed program for financial monitoring at the Regional, District and Sub-recipients levels, and shall require a report to be prepared and submitted as part of the Principal Recipient’s periodic reporting to the Global Fund. 30.Sep.13 Met This condition is overdue, however is well advanced for completion. The PR submitted a draft Internal Audit Plan and a Financial Monitoring Plan to the Global Fund on 20 March 2014. Subsequently the CT's finance officer had a follow up discussion with the PR finance manager. Final review of the documents is to be completed by end of May 2014. Condition Precedent Special condition 5: No later than 31 March 2014, the Principal Recipient shall submit to the Global Fund, in form and substance satisfactory to the Global Fund, a revised national monitoring and evaluation plan (the Revised National M&E Plan) which shall be updated to reflect the findings of the malaria program review and the update of the National Strategic Plan. The Revised National M&E Plan shall clearly articulate how the monitoring of the private sector is going to be strengthened and shall provide a specific time-bound action plan for the strengthening of this component. 31.Mar.14 Met The M&E Plan was submitted to the Global Fund on 1st April 2014. On 16th April 2014, the GF communicated its comments on the M&E plan to the PR. The comments were addressed and the final version of the revised M&E plan was submitted with the Malaria Concept Note submission. Condition Precedent Special condition 6: No later than 31 March 2014, the Principal Recipient shall provide to the Global Fund evidence, in form and substance satisfactory to the Global Fund, that it has developed and implemented a routine data quality audit, developed in collaboration with the institutional care division of the Ghana Health Service. The audit shall include a focus on completeness, timeliness and reliability of data. Semi-annual audit reports shall be submitted to the Global Fund as part of each Progress Update, including the identification of key gaps and remedial actions. 31.Mar.14 Met The PR, in collaboration with the Institutional Care Division and Policy Planning Monitoring and Evaluation Division of the Ghana Health Service, conducted a data quality audit during the period under review. First draft report on the data quality audit was submitted to the LFA on 19 March 2013. Condition Precedent Special condition 7: By no later than 30 June 2014, the Principal Recipient shall provide to the Global Fund evidence, in form and substance satisfactory to the Global Fund, that it has developed and implemented an improved ACT consumption monitoring and reporting mechanism, which shall document and verify ACT utilization and supply chain information for individual treatment doses. Data collected using the improved ACT consumption monitoring and reporting mechanism shall be used to revise forecasts for 2015 and following years. The improved system should capture treatment courses as opposed to number of tablets consumed as the case is now. 30.Jun.14 Not yet due. The PR is in the process of developing a monitoring system tracking consumption data which will inform forecast. The plan is to incorporate the tool in the DHIMS. It is part of the DHIMS tools review process. It is expected to be used in the next semester reporting. Met page 6 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 CP CP Type # Condition Precedent Functional Tied To Area Terminal Date Is curr Comments ently met? Condition Precedent Special condition 8: The Parties to this Agreement acknowledge that US$ 20,542,650 is reserved for direct copayments to manufacturers of ACTs, on behalf of private sector first-line buyers in Ghana, (the “Private Sector CoPayment”). Immediately upon establishment of modalities for the use of Grant funds for the Private Sector CoPayments, the Global Fund will communicate the modalities and appropriate guidance to the Principal recipient, following which the reserved amount may become available for disbursement subject to terms and conditions of this Agreement. 28.Feb.14 Met The PR received the Operational Policy Note (OPN) on Private Sector Co-Payment Mechanism from the Global Fund on 15 January 2014. Condition Precedent Special condition 9: At the time of each Progress Update (starting with the Progress Update for July -December 2013) the Principal Recipient shall submit to the Global Fund stock status reports for Global Fund financed Medicines and Health Products (the “Stock Reports”), in the form and substance satisfactory to the Global Fund. The Stock Report shall be based on an estimate monthly need of stock of medicines and health products and shall, without limitation, include the following information: a. Opening stock at the Central level; b. Receipts at the Central level c. Quantities issued to each Regional Medical Stores (RMS) d. Stock on hand at Central Level e. Opening Stock at each RMS f. Quantities received at the RMS g. Quantities issued to health facilities from each RMS h. Stock on hand at each RMS and total all RMS Met The PR submitted the stock levels of medicines and other health products at central medical and regional medical stores as at the end of December 2013 as part of the documents submitted to the Global Fund on 14 February for the PUDR review. There were however discrepancies in the information provided. CT''s PSM expert is currently following up with PR and LFA to resolve the issues prior to the next reporting period. Condition Precedent Special condition 10: Notwithstanding Article 15 of the Standard Terms and Conditions of this Agreement, the Parties agree that for the period of first 18 months of the Program the programmatic reports in relation to output/coverage indicators for which information is sourced from DHIMS (i.e. indicators number 8.2, 8.3, 8.4) shall be submitted to the Global Fund no later than 90 days after the end of each reporting period. The 90-day deadline shall decrease to 60 days beginning from month 19 of the Program and to 45 days starting from month 24. This Section shall have no effect on the Principal Recipient’s obligations to report on other objectives and targets of the Program no later than 45 days after the end of each reporting period, as per Article 15 of the Standard Terms and Conditions of this Agreement. Met Valid throughout the grant. The PR reported results for the indicators in the most recent PU/DR. Condition Precedent 5.1 The disbursement of Grant Funds by Procureme the Global Fund to the Principal Recipient nt for the supply chain strengthening activities is subject to satisfaction of each of the following requirements: (a) delivery by the Principal Recipient to the Global Fund of a detailed and costed plan for implementation of the supply chain strengthening activities (the “Supply Chain Plan”), developed in collaboration with the relevant stakeholders in the Republic of Ghana; and (b) the written approval by the Global Fund of the Supply Chain Plan. Not started page 7 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 CP CP Type # Condition Precedent Functional Tied To Area Terminal Date Is curr Comments ently met? Condition Precedent 5.2 Unless otherwise agreed by the Finance Global Fund in writing the Principal Recipient shall not undertake construction and/or renovation activities of any scale using Grant Funds, or savings, efficiencies, interest or revenues generated therefrom. Any investment or expenditure contrary to the above shall be deemed ineligible and spent in breach of this Grant Agreement. Not started Condition Precedent 5.3 The Principal Recipient Procureme acknowledges and agrees that all the nt warehousing and distribution of the Health Products financed by the Global Fund shall be handled by a third party contractor selected and contracted by the Global Fund and financed through the Grant Funds, until such time when the Global Fund in its sole discretion determines that other arrangements are acceptable. The Principal Recipient agrees to provide all the necessary information to and to fully cooperate with such third party contractor in discharging its obligations under the agreement concluded between the Global Fund and the contractor. Not started Condition Precedent 5.4 The use of Grant Funds by the M&E Principal Recipient to finance the surveys, research and other M&E activities in the amount of US$ 3,048,604.25 (the “M&E Activities”) is subject to satisfaction of each of the following requirements: (a) the delivery by the Principal Recipient to the Global Fund of a plan and a detailed budget for the implementation of the M&E (the “M&E Plan and Budget”), in form and substance satisfactory to the Global Fund, and developed in collaboration with technical partners in the Republic of Ghana; and (b) the written approval of the Global Fund of the M&E Plan and Budget. Not started 5.5 In accordance with the Global Fund Others Board Decision Point GF/B28/DP4, the Grantee acknowledges and agrees that the commitment and disbursement of 15% of the Republic of Ghana’s aggregate allocation of US$ 125,101,951 for the 2014-2016 allocation period, which is equal to US$ 18,765,292.65, is subject to the Global Fund’s satisfaction with the Republic of Ghana’s compliance with the Global Fund’s policies relating to counterpart financing. Not started 6.1 The Grantee and the Principal Others Recipient acting on behalf of the Grantee have all the necessary power and/or have been duly authorised by or obtained all necessary consents, actions, approval and authorisations to execute and deliver this Grant Confirmation and to perform all the obligations of the Grantee under this Grant Confirmation. The execution, delivery and performance by the Grantee or the Principal Recipient acting on behalf of the Grantee of this Grant Confirmation do not violate or conflict with any applicable law, any provision of its constitutional documents, any order or judgment of any court or any competent authority, or any contractual restriction binding on or affecting the Grantee or the Principal Recipient. Not started page 8 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 2. Key Grant Performance Information 2.1. Program Impact and Outcome Indicators Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 2012 2013 2014 2015 2016 2017 2018 2019 2020 Goal 1 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 2021 2012 2023 2024 2025 2026 To contribute to the overall national malaria strategic plan which aims at reducing malaria specific morbidity and mortality by 75% by the year 2015. Impact indicator All-cause under-5 mortality rate Baselines Value Year 80 per 1000 Live Births 2008 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Target N: D: P: % N: D: P: % N: 75 D: 1,000 P: 8% N: 75 D: 1,000 P: 8% N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Data source of Results Impact indicator Parasite prevalence in children 6-59 months by region and ecologic zone [RDT+ and Microscopy+] Year 1 Target Year 2 Baselin N: e D: Establis P: % hed Year 3 Year 4 N: N: D: D: P: 25% P: % Baselines Value Year 27.5% 2011 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 TBD N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result Data source of Results Outcome indicator Year 1 % of people in targeted areas sprayed with IRS in the last 12 months Year 2 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Year 6 2008 Year 7 N: D: P: % Year 5 Year 85% N: N: N: N: N: N: D: D: D: D: D: D: P: 90% P: 90% P: 90% P: 90% P: 90% P: % N: D: P: % Year 4 Value Target N: D: P: % Year 3 Baselines N: D: P: % Data source of Results Outcome indicator Year 1 % of U5 children (and other target group) with uncomplicated malaria correctly managed at health facilities Year 2 Year 3 Year 4 Year 5 Year 6 Baselines Value Year 22% 2008 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Target N: N: D: D: P: 55% P: % N: N: D: D: P: 70% P: % N: N: D: D: P: 80% P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Data source of Results page 9 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Outcome indicator Proportion of children under 5 years of age with fever in the last 2 weeks who received antimalarial treatment according to national treatment policy within 24 hours of onset of fever Year 1 Year 2 Year 3 Target N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % Year 4 18.2% 2008 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 N: N: N: N: D: D: D: D: P: 40% P: 65% P: 90% P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Year 6 Year Year 7 N: D: P: % Year 5 Baselines Value N: D: P: % Data source of Results Impact indicator % of children U5 sleeping under an ITN the previous night Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Baselines Value Year 28.2 2008 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Target N: N: D: D: P: 50% P: % N: N: N: N: D: D: D: D: P: 65% P: 75% P: 85% P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Data source of Results Impact indicator % of pregnant women (and other target groups) sleeping under an ITN the previous night Year 1 Year 2 Year 4 2008 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 N: N: N: N: D: D: D: D: P: 65% P: 75% P: 85% P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Year 6 Year 2.6% N: N: D: D: P: 50% P: % N: D: P: % Year 5 Value Target N: D: P: % Year 3 Baselines N: D: P: % Data source of Results Outcome indicator Year 1 % of households with at least one ITN the previous night Year 2 Year 3 Year 4 Year 5 Year 6 Baselines Value Year 32.6 2008 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Target N: N: D: D: P: 65% P: % N: N: N: N: D: D: D: D: P: 65% P: 95% P: 85% P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Data source of Results page 10 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Outcome indicator Year 1 Percentage of pregnant women who received at least 2 doses of SP during their last pregnancy Year 2 Year 3 Year 4 Year 5 Year 6 Baselines Value Year 64.6 2008 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Target N: N: D: D: P: 65% P: % N: N: N: N: D: D: D: D: P: 75% P: 90% P: 85% P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Data source of Results Impact indicator Percentage of people who know the cause of, symptoms of, treatment for or preventive measures for malaria Baselines Value Year 22% Percentage of people who know the cause of, symptoms of, treatment for or preventive measures for malaria Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 2004 Baselines Value Year 22% 2004 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Target N: N: D: D: P: 65% P: % N: N: D: D: P: 85% P: % N: N: D: D: P: 90% P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Data source of Results Impact indicator Malaria test positivity rate Baselines Value Year 80 per 1000LB Year 1 Year 2 Target N: D: P: % Result N: D: P: % Year 3 Year 6 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 N: N: N: N: D: D: D: D: P: 50% P: 48% P: 45% P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Year 4 N: D: P: % Year 5 N: D: P: % Data source of Results Impact indicator Inpatient malaria cases per 1000 persons per year Baselines Value Year Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Target N: D: P: % N: 10 D: 1,000 P: 1% N: 10 D: 1,000 P: 1% N: 9 D: 1,000 P: 1% N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Data source of Results page 11 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Impact indicator Inpatient malaria deaths per 1000 persons per year Baselines Value Year Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 Target N: D: P: % N: D: P: % N: 0 D: 1,000 P: 0% N: 0 D: 1,000 P: 0% N: 0 D: 1,000 P: 0% N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Data source of Results Outcome indicator Percentage of children under 5 years old with fever in the last 2 weeks who received antimalarial treatment according to national policy within 24 hours of the onset of fever Year 1 Year 2 Year 3 Year 4 Target N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % Year 5 Baselines Value Year 12.10 2008 Year 6 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 N: N: D: D: P: 65% P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Data source of Results Impact indicator Percentage of pregnant women who received 2 doses of intermittent preventive treatment for malaria during ANC visits during their last pregnancy Year 1 Year 2 Year 3 Year 4 Target N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % Year 5 Baselines Value Year 44.10% 2008 Year 6 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 N: N: D: D: P: 90% P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Data source of Results Outcome indicator Percentage of individuals who slept under an insecticide-treated net the previous night Year 1 Year 2 Year 3 Year 4 Target N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % Year 5 Baselines Value Year 28.6% 2011 Year 6 Year 7 Year 8 Year 9 Year 10 Year 11 Year 12 Year 13 Year 14 Year 15 N: N: D: D: P: 75% P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Data source of Results page 12 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 2.2. Programmatic Performance 2.2.1. Reporting Periods N/A Period 1 Period 2 Period 3 Period 4 Period 5 Period 6 Period 7 Period 8 01.Jul.11 31.Dec.11 01.Jan.12 30.Jun.12 01.Jul.12 31.Dec.12 01.Jan.13 30.Jun.13 01.Jul.13 31.Dec.13 01.Jan.14 30.Jun.14 01.Jul.14 31.Dec.14 01.Jan.15 30.Jun.15 2.2.2. Program Objectives, Service Delivery Areas and Indicators Objective 1 - To promote prompt and effective treatment of malaria by increasing the proportion of malaria patients receiving treatment with the recommended antimalarials in health facilities from 30-75% in children under five years and 45-90% in adults by 2014 Treatment: Prompt, effective antimalarial treatment Indicator 1.1 - Number and percentage of outpatient malaria cases (both suspected and confirmed) treated with ACTs. Baseline Value No Level Year 68% Period 1 2011 Period 2 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) Top 10 Equ. N Period 3 Period 4 Period 5 Period 6 Period 7 Period 8 Target N: 8,743,127 D: 12,490,182 P: 70% N: 6,336,960 D: 7,921,200 P: 80% N: 12,673,920 D: 15,842,400 P: 80% N: 5,752,540 D: 6,930,771 P: 83% N: 7,752,000 D: 9,120,000 P: 85% N: 3,793,635 D: 4,360,500 P: 87% N: 8,310,600 D: 9,234,000 P: 90% N: 3,728,228 D: 4,142,475 P: 90% Result Pending result N: 1,138,351 D: 1,374,613 P: 83% N: 6,039,197 D: 7,335,973 P: 82% N: 3,393,890 D: 5,554,040 P: 61% N: 6,439,442 D: 9,120,000 P: 71% N: 3,030,392 D: 3,484,013 P: 87% N: 6,194,316 D: 741,606 P: 835% N: D: P: % Indicator 1.2 - Number of health workers from targeted public and private health facilities given refresher training on malaria case management Baseline Value No Level Year 1766 Period 1 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) N N 2011 Period 2 Period 3 Period 4 Target 50 40 90 Result Pending result 0 0 Period 5 Period 6 Period 7 Period 8 0 Indicator 1.3 - Proportion of Health facilities (public and private) with NO reported stock-out lasting more than one week of nationally-recommended antimalarial drugs at anytime during the past six months Baseline Value No Level Year 99.7% Period 1 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) N N 2011 Period 2 Period 3 Period 4 Period 5 Period 6 Period 7 Period 8 Target N: 3,185 D: 3,217 P: 99% N: 3,185 D: 3,217 P: 99% N: 3,185 D: 3,217 P: 99% N: 3,185 D: 3,217 P: 99% N: 3,185 D: 3,217 P: 99% N: 3,181 D: 3,213 P: 99% N: 3,181 D: 3,213 P: 99% N: 3,181 D: 3,213 P: 99% Result Pending result N: 2,504 D: 3,217 P: 78% N: 3,217 D: 3,217 P: 100% N: 3,217 D: 3,217 P: 100% N: 3,438 D: 3,474 P: 99% N: 3,374 D: 3,374 P: 100% N: 3,181 D: 3,181 P: 100% N: D: P: % Period 9 Period 10 Period 11 Period 12 Period 13 Period 14 Period 15 Period 16 Target N: 3,181 D: 3,213 P: 99% N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: D: P: % page 13 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Indicator 1.4 - Number of both public and private supervisory visits (4 pharmacist recruited to monitor AMFm drugs) Baseline Value No Level Year 483 Period 1 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) N N 2011 Period 2 Period 3 Period 4 Period 5 Target 750 850 1,020 1,020 Result Pending result 731 1,164 Pending result Period 6 Period 7 Period 8 Period 6 Period 7 Period 8 Indicator 1.5 - Proportion of suspected malaria cases confirmed by RDTs or microscopy Baseline Value No Level Year 49.5% Period 1 2011 Period 2 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) Top 10 Equ. N Period 3 Period 4 Period 5 Target N: 5,019,040 D: 9,652,001 P: 52% N: 4,356,600 D: 7,921,200 P: 55% N: 9,505,440 D: 15,842,400 P: 60% N: 4,505,002 D: 6,930,771 P: 65% N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result Pending result N: 520,008 D: 1,374,613 P: 38% N: 2,734,965 D: 7,335,973 P: 37% N: 2,198,470 D: 5,554,040 P: 40% N: D: P: % N: D: P: % N: D: P: % N: D: P: % Indicator 1.6 - Phase 2 - Proportion of expected malaria seen at the health facilities Baseline Value No Level Year 7921200 /114000 00 60% Period 1 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) N N 2012 Period 2 Period 3 Period 4 Period 5 Period 6 Period 7 Period 8 Target N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: 9,120,000 D: 11,400,000 P: 80% N: 4,360,500 D: 5,130,000 P: 85% N: 9,234,000 D: 10,260,000 P: 90% N: 4,142,475 D: 4,360,500 P: 95% Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: 11,331,522 D: 11,400,000 P: 99% N: 3,484,013 D: 5,130,000 P: 68% N: 7,416,060 D: 10,260,000 P: 72% N: D: P: % Indicator 1.9 - Phase 2 - Percentage of reported suspected malaria cases that received a parasitological test( RDTs or microscopy) Baseline Value No Level 2735457 /720818 9 ---37.9% Period 1 Year 2012 Period 2 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) Top 10 Equ. N Period 3 Period 4 Period 5 Period 6 Period 7 Period 8 Target N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: 5,472,000 D: 9,120,000 P: 60% N: 3,052,350 D: 4,360,500 P: 70% N: 6,463,800 D: 9,234,000 P: 70% N: 3,106,859 D: 4,142,475 P: 75% Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: 4,926,969 D: 11,331,522 P: 44% N: 2,389,063 D: 3,484,013 P: 69% N: 5,583,313 D: 7,416,060 P: 75% N: D: P: % page 14 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Objective 2 - To provide IPT (at least 2 doses) in 95% of pregnant women by 2014 Prevention: Malaria in pregnancy Indicator 2.1 - % of pregnant women on Intermittent preventive treatment (at least two doses of SP) according to national policy Baseline Value No Level 39.7% Period 1 Year 2011 Period 2 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) Top 10 Equ. N Period 3 Period 4 Period 5 Period 6 Period 7 Period 8 Target N: 778,720 D: 973,401 P: 80% N: 399,874 D: 499,842 P: 80% N: 799,746 D: 999,683 P: 80% N: 410,670 D: 513,337 P: 80% N: 764,010 D: 955,012 P: 80% N: 4,152,579 D: 4,885,387 P: 85% N: 83,051,092 D: 9,770,773 P: 850% N: D: P: % Result Pending result N: 289,974 D: 474,589 P: 61% N: 562,099 D: 972,873 P: 58% N: 323,178 D: 521,936 P: 62% N: 494,789 D: 969,123 P: 51% N: 151,249 D: 501,315 P: 30% N: 372,091 D: 960,731 P: 39% N: D: P: % page 15 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Objective 3 - To increase LLIN use among the general public in the country especially in children under 5 years (from 21.8% to 80%), pregnant women (from 46.3% to 80%) by the end of the year 2014. Prevention: Insecticide-treated nets (ITNs) Indicator 3.1 - Number of Long Lasting Nets (LLNs) distributed to people Baseline Value No Level Year 3413360 Period 1 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) Y N 2011 Period 2 Period 3 Period 4 Period 5 Target 4,491,282 4,514,354 7,202,338 828,926 Result Pending result 4,689,599 7,631,068 1,241,370 Period 6 Period 7 Period 8 1,617,087 Indicator 3.2 - Phase 2 - TOTAL Number of Long Lasting Nets (LLNs) distributed to pupils, Pregnant women and children under five years Baseline Value No Level 7874094 Period 1 Period 2 Year 2012 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) Top 10 Equ. N Period 3 Period 4 Period 5 Period 6 Period 7 Period 8 Target 828,926 825,925 3,502,523 7,007,050 Result Pending result 1,617,087 1,783,112 5,172,812 1,377,988 page 16 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Objective 4 - To strengthen the monitoring & evaluation and operational research in malaria treatment, IPT and LLINs HSS: Information system & Operational research Indicator 4.1 - Number of staff trained in data management or general M&E at national and sub-national level Baseline Value No Level Year 268 Period 1 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) N N 2011 Period 2 Period 3 Period 4 Period 5 Target 356 0 0 0 Result Pending result 0 0 0 Period 6 Period 7 Period 8 Indicator 4.2 - Percentage (%) of health facilities submitting timely and complete reports (on ACTs) to the district level Baseline Value No Level 707/520 013.6% Period 1 Year Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) N N 2012 Period 2 Period 3 Period 4 Period 5 Period 6 Period 7 Period 8 Target N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: 1,446 D: 3,213 P: 45% N: 1,767 D: 3,213 P: 55% N: 2,088 D: 3,213 P: 65% N: 2,249 D: 3,213 P: 70% Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: 13,588 D: 42,108 P: 32% N: 55 D: 74 P: 74% N: 2,088 D: 2,677 P: 78% N: D: P: % page 17 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Objective 6 - To provide prompt and effective treatment of malaria to children under five years in 123 underserved districts through community-based care by 2013 Treatment: Home-based management of malaria Indicator 6.1 - Number of uncomplicated malaria cases among under 5 year children treated with ACT by community based health workers (CBA) Baseline Value No Level Year 0 Period 1 2011 Period 2 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) Top 10 Equ. N Period 3 Period 4 Period 5 Period 6 Period 7 Period 8 Target 1,031,445 747,615 1,416,175 747,615 121,400 64,589 129,178 Result Pending result 0 92,636 65,963 129,316 46,036 121,864 21,529 Indicator 6.2 - Number of Community Health Officers trained in HBC using Artesunate Amodiaquine Baseline Value No Level Year 125 Period 1 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) N N 2011 Period 2 Period 3 Period 4 Period 5 Target 820 50 140 0 Result Pending result 532 742 0 Period 6 Period 7 Period 8 Period 7 Period 8 Indicator 6.3 - Number of Community Drug Distributors trained in HBC using Artesunate Amodiaquine Baseline Value No Level Year 0 Period 1 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) N N 2011 Period 2 Period 3 Period 4 Period 5 Target 8,500 1,165 3,346 0 Result Pending result 3,108 4,256 0 Period 6 Indicator 6.4 - Proportion of Community Drug Distributors with NO reported stock out of artesunate-amodiaqine lasting more than one week at anytime during the past Six months Baseline Value No Level Year N/A Period 1 Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) N N 2011 Period 2 Period 3 Period 4 Period 5 Period 6 Period 7 Period 8 Target N: 5,194 D: 6,493 P: 80% N: 7,225 D: 8,500 P: 85% N: 8,400 D: 9,665 P: 87% N: 8,400 D: 9,665 P: 87% N: D: P: % N: D: P: % N: D: P: % N: D: P: % Result Pending result N: 8,500 D: 8,500 P: 100% N: 7,925 D: 9,665 P: 82% Pending result N: D: P: % N: D: P: % N: D: P: % N: D: P: % page 18 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 CSS: Monitoring and documentationof community and government interventions Indicator 6.6 - Proportion of CDD/CBA reporting out of the total number of functional CDD/CBA in the country Baseline Value No Level Year Is Top 10 indicator? (Y/N) Is Training indicator? (Y/N) N N 5250/60 00 -87.5% Period 1 Period 2 Period 3 Period 4 Period 5 Period 6 Period 7 Period 8 Target N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: 5,250 D: 6,000 P: 88% N: 5,250 D: 6,000 P: 88% N: 5,250 D: 6,000 P: 88% N: 5,250 D: 6,000 P: 88% Result N: D: P: % N: D: P: % N: D: P: % N: D: P: % N: 11,809 D: 14,016 P: 84% N: 6,577 D: 7,464 P: 88% N: 5,250 D: 6,091 P: 86% N: D: P: % page 19 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 2.2.3. Cumulative Progress To Date Latest reporting due period : 7 (01.Jul.14 - 31.Dec.14) Objective 1 To promote prompt and effective treatment of malaria by increasing the proportion of malaria patients receiving treatment with the recommended antimalarials in health facilities from 30-75% in children under five years and 45-90% in adults by 2014 SDA Treatment: Prompt, effective antimalarial treatment Indicator 1.1 - Number and percentage of outpatient malaria cases (both suspected and confirmed) treated with ACTs. 60% N: 6,194,316 D: 741,606 P: 835.3 % N: 8,310,600 D: 7 9,234,000 P: 90 % 7 Value 30% Period 0% No Level Result Value 100% 90% Target Period 120% Indicator 1.2 - Number of health workers from targeted public and private health facilities given refresher training on malaria case management 3 Value 60% 90 Period 30% 3 Value 0% Period No Level Result 100% 90% Target 0% 0 Indicator 1.3 - Proportion of Health facilities (public and private) with NO reported stock-out lasting more than one week of nationallyrecommended antimalarial drugs at anytime during the past six months Value 60% 7 Period 30% Value N: 3,181 D: 3,213 P: 99 % 0% Period No Level Result 100% 90% Target N: 3,181 D: 3,181 P: 100 % 7 101% Indicator 1.4 - Number of both public and private supervisory visits (4 pharmacist recruited to monitor AMFm drugs) 3 Value 60% 1,020 Period 30% 3 Value 0% Period No Level Result 100% 90% Target 114% 1,164 Indicator 1.5 - Proportion of suspected malaria cases confirmed by RDTs or microscopy 4 Value 60% Period 30% Value N: 4,505,002 D: 4 6,930,771 P: 65 % 0% Period No Level Result 100% 90% Target N: 2,198,470 D: 5,554,040 P: 39.6 % 61% Indicator 1.6 - Phase 2 - Proportion of expected malaria seen at the health facilities Result 7 60% N: 9,234,000 D: 7 10,260,00 0 P: 90 % Value 30% Period 0% No Level Value 100% 90% Target Period N: 7,416,060 D: 10,260,00 0 P: 72.3 % 80% Indicator 1.9 - Phase 2 - Percentage of reported suspected malaria cases that received a parasitological test( RDTs or microscopy) N: 5,583,313 D: 7,416,060 P: 75.3 % 60% Value 30% 7 N: 6,463,800 D: 7 9,234,000 P: 70 % Result Period 0% No Level Value 100% 90% Target Period 108% page 20 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Objective 2 To provide IPT (at least 2 doses) in 95% of pregnant women by 2014 SDA Prevention: Malaria in pregnancy Indicator 2.1 - % of pregnant women on Intermittent preventive treatment (at least two doses of SP) according to national policy 7 Value 60% Period 30% Value N: 83,051,09 2 7 D: 9,770,773 P: 850 % 0% Period No Level Result 100% 90% Target N: 372,091 D: 960,731 P: 38.7 % 5% Objective 3 To increase LLIN use among the general public in the country especially in children under 5 years (from 21.8% to 80%), pregnant women (from 46.3% to 80%) by the end of the year 2014. SDA Prevention: Insecticide-treated nets (ITNs) Indicator 3.1 - Number of Long Lasting Nets (LLNs) distributed to people 828,926 4 Value 60% 4 Period 30% No Level Value 0% Period Result 100% 90% Target 120% 1,241,370 Indicator 3.2 - Phase 2 - TOTAL Number of Long Lasting Nets (LLNs) distributed to pupils, Pregnant women and children under five years 60% 7,007,050 7 Value 30% 7 Period 0% No Level Result Value 100% 90% Target Period 74% 5,172,812 Objective 4 To strengthen the monitoring & evaluation and operational research in malaria treatment, IPT and LLINs SDA HSS: Information system & Operational research Indicator 4.1 - Number of staff trained in data management or general M&E at national and sub-national level 3 60% 0 Value 30% 3 Period 0% No Level Result Value 100% 90% Target Period Cannot Calculate 0 Indicator 4.2 - Percentage (%) of health facilities submitting timely and complete reports (on ACTs) to the district level N: 2,088 D: 3,213 P: 65 % 7 Value N: 2,088 D: 2,676.9 P: 78 % 60% 7 Period 30% No Level Value 0% Period Result 100% 90% Target 120% page 21 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Objective 6 To provide prompt and effective treatment of malaria to children under five years in 123 underserved districts through community-based care by 2013 SDA Treatment: Home-based management of malaria Indicator 6.1 - Number of uncomplicated malaria cases among under 5 year children treated with ACT by community based health workers (CBA) 7 Value 60% 129,178 Period 30% 7 Value 0% Period No Level Result 100% 90% Target 94% 121,864 Indicator 6.2 - Number of Community Health Officers trained in HBC using Artesunate Amodiaquine 140 3 Value 60% 3 Period 30% No Level Value 0% Period Result 100% 90% Target 120% 742 Indicator 6.3 - Number of Community Drug Distributors trained in HBC using Artesunate Amodiaquine Period 3 Value 60% Value 3,346 30% 3 0% Period No Level Result 100% 90% Target 120% 4,256 Indicator 6.4 - Proportion of Community Drug Distributors with NO reported stock out of artesunate-amodiaqine lasting more than one week at anytime during the past Six months 60% Value 30% Period N: 7,925 D: 9,664.6 P: 82 % N: 8,400 D: 9,665 3 P: 86.9 % 3 SDA Value 0% Period No Level Result 100% 90% Target 94% CSS: Monitoring and documentationof community and government interventions Indicator 6.6 - Proportion of CDD/CBA reporting out of the total number of functional CDD/CBA in the country N: 5,250 D: 6,090.5 P: 86.2 % 60% N: 5,250 D: 6,000 7 P: 87.5 % Value 30% 7 Result Period 0% No Level Value 100% 90% Target Period 99% page 22 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 2.3. Financial Performance 2.3.1. Grant Financial Key Performance Indicators (KPIs) Grant Duration (months) 78 months Grant Amount % Time Elapsed (as of end date of the latest PU) 106,799,092 $ 46% % disbursed by TGF (to date) Time Remaining (as of end date of the latest PU) Expenditures Rate (as of end date of the latest PU) 74% 42 months Disbursed by TGF (to date) 79,001,773 $ 85% Funds Remaining (to date) 27,797,319 $ 2.3.2. Program Budget Budget Period 1 Period Covered From: Period Covered To: Budget Period 2 Budget Period 3 Budget Period 4 Budget Period 5 Budget Period 6 Budget Period 7 Budget Period 8 01.Jul.11 01.Oct.11 01.Jan.12 01.Apr.12 01.Jul.12 01.Oct.12 01.Jan.13 01.Apr.13 30.Sep.11 31.Dec.11 31.Mar.12 30.Jun.12 30.Sep.12 31.Dec.12 31.Mar.13 30.Jun.13 Currency: USD USD USD USD USD USD USD USD Cumulative Budget Through: 14,779,136 25,868,094 36,957,053 53,916,407 57,912,082 55,066,505 49,631,634 52,908,344 Summary Period Budget: 14,779,136 11,088,958 11,088,959 16,959,354 3,995,675 1,621,200 1,276,710 3,276,710 Budget Period 9 Budget Period 10 Budget Period 11 Budget Period 12 Expenditure Categories Program Activities Implementing Entities Period Covered From: Period Covered To: Summary Period Budget: Budget Period 14 Budget Period 15 Budget Period 16 01.Jul.13 01.Oct.13 01.Jan.14 01.Apr.14 01.Jul.14 01.Oct.14 01.Jan.15 01.Jan.16 30.Sep.13 31.Dec.13 31.Mar.14 30.Jun.14 30.Sep.14 31.Dec.14 31.Dec.15 31.Dec.16 USD USD USD USD USD USD USD USD 21,815,716 31,628,617 75,673,535 82,516,962 89,712,625 73,641,006 3,231,917 9,812,901 44,044,918 6,843,427 7,195,663 6,857,096 Currency: Cumulative Budget Through: Budget Period 13 121,258,783 121,258,783 47,617,777 Expenditure Categories Program Activities Implementing Entities - Comments and additional information 2.3.3. Program Expenditures page 23 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Actual Cash Outflow Period PU6: 01.Jan.14 - 30.Jun.14 1. Total cash outflow vs. budget $ 1,718,603 1a. PR's Total expenditure Cumulative Budget $ 82,516,962 Cumulative Cash Outflow $ 70,191,611 $ 1,484,407 $ 65,647,723 $ 234,196 $ 4,543,888 1b. Disbursements to sub-recipients Variance Reason for variance $ 12,325,351 Reason for adjustments 1c. Expenditure Adjustments 2. Pharmaceuticals & Health Product expenditures vs budget $ 48,642,089 2a. Medicines & pharmaceutical products $ 16,964,203 2b. Health products and health equipment $ 31,677,886 2.3.4. Cumulative Program Budget, Expenditures and Disbursement to Date 2.4. Progress Update and Disbursement Information Rating A1 A2 B1 B2 C Description Exceeding expectations Meeting expectations Adequate Inadequate but potential demonstrated Unacceptable page 24 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Progress Updates TGF Rating PU PU Period 1 Disbursement Information 01.Jul.11 31.Mar.12 B2 Summary of Progress DR DR Period Covered PR Request Disbursement Disbursement Amount Date 01.Apr.12 31.Dec.12 1 N/A Reasons for variance between PR Request and Actual Disbursement Detailed reporting for this program is under the GHN- NIL - Detailed reporting for this program is under the GHN-405-G04-M for 405-G04-M. As the grant was in the process of shift this period. to the SSF agreement till mid 2012. When signed SSF grant was backdated to 1 July 2011 as guided by the GF SSF/Architecture team. Progress Updates PU PU Period 2 01.Apr.12 30.Jun.12 Summary of Progress Disbursement Information TGF Rating B1 DR 2 DR Period Covered 01.Jul.12 31.Mar.13 PR Request 14,231,176 Disbursement Disbursement Amount Date $ 3,418,177 14 Dec 2012 Reasons for variance between PR Request and Actual Disbursement This grant includes all scope of interventions for Disbursement directly to VPP procurement agent IDA Foundation - amount malaria vector control in Ghana (incl. ACT (under is designated for procurement of LLIN AMFM) and IPT treatment, RDT, LLIN (aiming universal coverage) and various trainings). The Principal Recipient is MoH (Ghana Health Services) and has a structure covering all districts of Ghana. As of 2010 Ghana received an AMFM grant through which PR as well as a number of Private sector “1st line buyers” are to receive subsidies on the procurements for ACTs therefore there has been a large influx of cheap ACTs in public and private health facilities across the country mainly through private sector suppliers, as the procurements within MOH where delayed. That has brought challenges in coordination and data collection of number of people treated with ACT in country. PR is also coordinating the mass bed-net distribution in country aiming to achieve universal coverage by end of 2012. This campaign is funded by various donors including The Global Fund (60% of total) through this grant. Both AMFM and mass LLIN campaigns increase complexity of reporting for the Principal Recipient. It has been noted that PU/DR reports have been submitted with significant delays and of low quality. LFA and GF had to engage in numerous clarifications with PR to finalise the reviews of the reports. Overall Performance: PR has made significant efforts and progress to maintain good operational level of national malaria program despite significant delays with procurement of health products and thus shortened time for implementation. Overall Top 10 indicator rating is B1. Most non Top 10 indicators are achieved or overachieved. PR collaborates well with national and international partners to ensure program functions in coherence with commonly agreed standards. page 25 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Progress Updates TGF Rating PU PU Period 2 Disbursement Information 01.Apr.12 30.Jun.12 B1 Summary of Progress DR DR Period Covered 01.Jul.12 29.Mar.13 4 01.Jul.12 31.Dec.12 $ 11,402,012 14 Dec 2012 Disbursement directly to VPP procurement agent PFSCM - amount is designated for procurement of ACT and RDT. This is different from the LFA recommended amount (US$ NIL) as the LFA did not recommend the disbursement to the PR due to the significant cash balance. In addition the LFA did not have an agreed PSM plan and signed price quotes at the time of PU/DR verification, therefore was not in a position to recommend a disbursement for VPP procurement. Progress Updates 3 14,231,176 Disbursement Disbursement Amount Date Reasons for variance between PR Request and Actual Disbursement This grant includes all scope of interventions for malaria vector control in Ghana (incl. ACT (under AMFM) and IPT treatment, RDT, LLIN (aiming universal coverage) and various trainings). The Principal Recipient is MoH (Ghana Health Services) and has a structure covering all districts of Ghana. As of 2010 Ghana received an AMFM grant through which PR as well as a number of Private sector “1st line buyers” are to receive subsidies on the procurements for ACTs therefore there has been a large influx of cheap ACTs in public and private health facilities across the country mainly through private sector suppliers, as the procurements within MOH where delayed. That has brought challenges in coordination and data collection of number of people treated with ACT in country. PR is also coordinating the mass bed-net distribution in country aiming to achieve universal coverage by end of 2012. This campaign is funded by various donors including The Global Fund (60% of total) through this grant. Both AMFM and mass LLIN campaigns increase complexity of reporting for the Principal Recipient. It has been noted that PU/DR reports have been submitted with significant delays and of low quality. LFA and GF had to engage in numerous clarifications with PR to finalise the reviews of the reports. Overall Performance: PR has made significant efforts and progress to maintain good operational level of national malaria program despite significant delays with procurement of health products and thus shortened time for implementation. Overall Top 10 indicator rating is B1. Most non Top 10 indicators are achieved or overachieved. PR collaborates well with national and international partners to ensure program functions in coherence with commonly agreed standards. PU PU Period PR Request Disbursement Information TGF Rating B1 Summary of Progress PR has made significant efforts and progress to maintain the good operational level of the national malaria program despite significant delays with procurement of health products and thus shortened time for implementation. All relevant conditions for this disbursement have been fulfilled, apart from the PSM plan approval and condition on costs to be used to fund SCMP. Please find attached the latest status of Condition Precedent and Special Conditions attached in the separed document. DR 5 DR Period Covered 01.Jan.13 30.Jun.13 PR Request 1,146,051 Disbursement Disbursement Amount Date $ 3,752,561 08 May 2013 Reasons for variance between PR Request and Actual Disbursement Total Country team verified forecast for the period of the DR request is: 1) Human Resources - US$ 204,053 2) Training US$ 57,116 (as per latest approved training plan) 3) Medicine&Pharma Products US$ 2,193,582 4) Communication Materials - US$ 767,860 5) Infrastructure and Other Equipment-US$ 1,412,714 6) Monitoring and Evaluation-US$ 1,758,437 7) Overheads-US$ 4,008 8) Planning and Administration-US$ 620,901 9) PSM costs- US$ 889,622 Total: US$ 7,908,293 Less verified cash at PR level: US$ 4,155,732 Amount to be disbursed to PR: US$ 3,752,561. * The grant is currently in the extension period of implementation, ending June 30, 2013. The Country Team expects the Global Fund Board to make a final decision on renewal of this grant by 1st week of May 2013. Provided the decision is positive the CT plans to finalize the grant agreement signing prior June 30th 2013, to ensure no disruption in the grant implementation. Note is made to the fact that there is an amount of $4,918,146 in favour the PR at VPP that would be off-set from the next VPP disbursement. page 26 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Progress Updates TGF Rating PU PU Period 3 Disbursement Information 01.Jul.12 31.Dec.12 B1 Summary of Progress DR 5.1 DR Period Covered 01.Jan.13 30.Jun.13 PR Request 1,146,051 Disbursement Disbursement Amount Date $ 17,091,755 25 Sep 2013 Reasons for variance between PR Request and Actual Disbursement PR has made significant efforts and progress to Disbursement to VPP for products (LLIN and RDT) - based on maintain the good operational level of the national countersigned price quotes malaria program despite significant delays with procurement of health products and thus shortened time for implementation. All relevant conditions for this disbursement have been fulfilled, apart from the PSM plan approval and condition on costs to be used to fund SCMP. Please find attached the latest status of Condition Precedent and Special Conditions attached in the separed document. Progress Updates TGF Rating PU PU Period 4 Disbursement Information 01.Jan.13 30.Jun.13 B1 Summary of Progress DR DR Period Covered 01.Jul.13 30.Sep.14 6 PR Request 62,460,428 Disbursement Disbursement Amount Date $ 10,971,048 04 Nov 2013 Reasons for variance between PR Request and Actual Disbursement Disbursement to VPP (PFSCM) for the procurement of ACT and antimlarials. Progress Updates PU PU Period 4 01.Jan.13 30.Jun.13 Summary of Progress Disbursement Information TGF Rating B1 DR 6.1 DR Period Covered 01.Jul.13 30.Sep.14 PR Request 62,460,428 Disbursement Disbursement Amount Date $ 4,713,394 26 Mar 2014 Reasons for variance between PR Request and Actual Disbursement The amount is released to PR and is calculated as follows: Funds for HR, Training, Infr.& equipment, M&E, P&A US$4,792,779 (July 2013- September 2014); Partial PSM costs for PR: US$ 2,736,079. Total PSM/transportation costs for PR are US$ 5,472,157, however the deliveries of goods are staggered through 2014 hence for the purpose of planning the PSM cost for PR was split in two equal tranches, 2nd part will be disbursed in Q2 of 2014; DHIMs strengthening: Original amount provisioned in the disbursement was for US$ 2,015,000 according to the summary budget (category "other"). The release of this amount was tied to completion of the relevant CP (#3 in the grant agreement). Hoverer, after the clarification, an amount of US$529,224 of additional funding for DHIMS strengthening was approved by the Global Fund. Hence the total amount for current disbursement is reduced. Rest of the funds (US$ 1,485,776) will be reserved for further reinvestment according to the areas of need. Less: Cash balance at PR account as at 30 June 2013 US$ 3,302,996. Less: US$41,692 from the infrastructure and equipment budget for improving storage conditions in selected regional medical stores. This item is reserved for the moment due to an ongoing investigation of the RMS renovation costs by the OIG. Total funds transferred to the PR are US$ 4,713,394. page 27 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Progress Updates TGF Rating PU PU Period 4 Disbursement Information 01.Jan.13 30.Jun.13 B1 Summary of Progress DR 6.2 DR Period Covered 01.Jul.13 30.Sep.14 PR Request 62,460,428 Disbursement Disbursement Amount Date $ 1,527,570 27 May 2014 Reasons for variance between PR Request and Actual Disbursement The amount is released for conducting survey and improving of storage conditions in selected regional medical stores Progress Updates TGF Rating PU PU Period 5 Disbursement Information 01.Jul.13 31.Dec.13 B1 Summary of Progress DR 6.3 DR Period Covered 01.Jul.13 30.Sep.14 PR Request 62,460,428 Disbursement Disbursement Amount Date $ 145,436 05 Sep 2014 Reasons for variance between PR Request and Actual Disbursement For this reporting period the program performance is This cash transfer is a part of the payment to John Snow Inc for the their acceptable and is rated B1. services rendered. AVG performance on TOP TEN indicators is 89% (B1) AVG performance ALL indicators is 93% (A2) Overall indicator performance is B1 (Top 10 rating outweighs non-Top 10) Progress Updates TGF Rating PU PU Period 6 Disbursement Information 01.Jan.14 30.Jun.14 DR DR Period Covered PR Request Disbursement Disbursement Amount Date B1 Summary of Progress N/A Reasons for variance between PR Request and Actual Disbursement For this reporting period the program performance is acceptable and is rated B1. AVG performance on TOP TEN indicators is 65% (B1) AVG performance ALL indicators is 81% (B1) Overall indicator performance is B1 (Top 10 rating outweighs non-Top 10) Progress Updates TGF Rating PU PU Period 7 01.Mar.15 - DR DR Period Covered 01.Mar.15 31.Dec.15 11 PR Request Disbursement Disbursement Amount Date 1 N/A Summary of Progress Reasons for variance between PR Request and Actual Disbursement Progress Updates Disbursement Information PU PU Period 7 Disbursement Information 01.Mar.15 Summary of Progress TGF Rating DR 12 DR Period Covered 01.Mar.15 31.Dec.15 PR Request 1 Disbursement Disbursement Amount Date N/A Reasons for variance between PR Request and Actual Disbursement page 28 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 Progress Updates TGF Rating PU PU Period 7 Disbursement Information 01.Mar.15 - DR 7 Summary of Progress DR Period Covered PR Request 01.Mar.15 31.Dec.15 47,617,778 Disbursement Disbursement Amount Date $ 13,715,980 23 Jun 2015 Reasons for variance between PR Request and Actual Disbursement This is the 1st release of the ADMF under the NFM grant. 2.5. Contextual Information Title Explanatory Notes 2.6. Phase 2/ Periodic Review Grant Renewal Performance Rating Recommendation Category Rationale for Phase 2/ Periodic Review Recommendation Category Rationale for Phase 2/ Periodic Review Recommendation Amount Time-bound Actions Issues Description page 29 of 30 Grant Performance Report External Print Version GHA-M-MOH Last Updated on: 02 July 2015 page 30 of 30